SCHEMBL744123

SCHEMBL744123

NC(=O)C1CCC(CN2C(=O)C=CC2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 5/20 0.36
CYP2C19 P33261 2/20 0.36
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
BLM P54132 1/20 0.36
WRN Q14191 1/20 0.36
HIF1A Q16665 1/20 0.36
BACE1 P56817 1/20 0.35
BACE2 Q9Y5Z0 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
POLB P06746 2/20 0.34
PKM P14618 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
APEX1 P27695 1/20 0.33
CYP1B1 Q16678 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16072051 1.00 SMN1; SMN2 (0.37) SMN1; SMN2ALDH1A1CYP2C19HPGDCYP1A2
SCHEMBL16483737 0.89 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1CYP2C19HPGDCYP1A2
SCHEMBL159817 0.84 LMNA (0.46) ALDH1A1CYP2C19HPGDCYP1A2BLM
SCHEMBL890390 0.84 LMNA (0.46) ALDH1A1CYP2C19HPGDCYP1A2BLM
SCHEMBL485615 0.83 MGLL (0.44) SMN1; SMN2ALDH1A1HPGDBLMPKM
Hydrochloric Acid SCHEMBL25415692 0.83 LMNA (0.44) ALDH1A1CYP2C19HPGDCYP1A2BLM
SCHEMBL18033768 0.83 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1CYP2C19HPGDCYP1A2
SCHEMBL18963599 0.83 ALDH1A1 (0.36) ALDH1A1CYP2C19HPGDCYP1A2BLM
SCHEMBL12013343 0.83 ALDH1A1 (0.40) ALDH1A1CYP2C19HPGDCYP1A2BLM
SCHEMBL24515098 0.83 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1CYP2C19HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711163-A2 DISPERSIONS PREPARED BY USE OF SELF-STABILIZING AGENTS BAXTER INTERNATIONAL INC. (US) 2006-10-18 EP claimed
EP-1605914-A1 METHOD FOR PREPARING SMALL PARTICLES BAXTER INTERNATIONAL INC. (US) 2005-12-21 EP claimed
US-20050196416-A1 Dispersions prepared by use of self-stabilizing agents BAXTER HEALTHCARE S.A. (CH) 2005-09-08 US claimed
WO-2005077337-A2 DISPERSIONS PREPARED BY USE OF SELF-STABILIZING AGENTS BAXTER INTERNATIONAL INC. (US) 2005-08-25 WO claimed
WO-2004082659-A1 METHOD FOR PREPARING SMALL PARTICLES BAXTER INTERNATIONAL INC. (US) 2004-09-30 WO claimed
US-20040022862-A1 Method for preparing small particles BAXTER INTERNATIONAL INC. 2004-02-05 US claimed
EP-0306168-A1 Preparation of radiolabeled conjugates IMMUNOMEDICS, INC. (US) 1989-03-08 EP claimed
EP-4746921-A1 DRUG CONJUGATES OF IMIDAZOQUINOLINE AMINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF Canwell Biotech Limited (CN) 2026-05-27 EP disclosed
EP-4720629-A1 FLOW CELL DEVICES AND OPTICAL SYSTEMS FOR IN SITU NUCLEIC ACID SEQUENCING Element Biosciences, Inc. (US) 2026-04-08 EP disclosed
US-20260078443-A1 FLOW CELL DEVICES AND OPTICAL SYSTEMS FOR IN SITU NUCLEIC ACID SEQUENCING ELEMENT BIOSCIENCES INC (US) 2026-03-19 US disclosed
CN-119546346-A Conjugate of camptothecins combined with DDX5 protein and acid sensitive joint and immune conjugate using the same 匹诺生物股份有限公司 2025-02-28 CN disclosed
CN-115103691-B Pharmaceutical composition containing antibody drug conjugate and application thereof 苏州盛迪亚生物医药有限公司 2025-01-24 CN disclosed
WO-2025015586-A1 DRUG CONJUGATES OF IMIDAZOQUINOLINE AMINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF CANWELL BIOTECH LIMITED (CN) 2025-01-23 WO disclosed
US-20040256749-A1 Process for production of essentially solvent-free small particles BAXTER INTERNATIONAL INC. 2004-12-23 US disclosed
US-20040245662-A1 Method for preparing submicron particles of antineoplastic agents BAXTER HEALTHCARE S.A. (CH) 2004-12-09 US disclosed
WO-2004103348-A2 SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS BAXTER INTERNATIONAL INC. (US) 2004-12-02 WO disclosed
WO-2004096180-A1 FORMULATION TO RENDER AN ANTIMICROBIAL DRUG POTENT AGAINST ORGANISMS NORMALLY CONSIDERED TO BE RESISTANT TO THE DRUG BAXTER INTERNATIONAL INC. (US) 2004-11-11 WO disclosed
WO-2004084860-A2 METHODS FOR THE COMMINUTION AND STABILIZATION OF SMALL PARTICLES IN SUSPENSION BAXTER INTERNATIONAL INC. (US) 2004-10-07 WO disclosed
WO-2004082659-A1 METHOD FOR PREPARING SMALL PARTICLES BAXTER INTERNATIONAL INC. (US) 2004-09-30 WO disclosed
US-20040022862-A1 Method for preparing small particles BAXTER INTERNATIONAL INC. 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078443-A1 FLOW CELL DEVICES AND OPTICAL SYSTEMS FOR IN SITU NUCLEIC ACID SEQUENCING DNMT3A, MTHFD1, CPSF6 SMN1; SMN2 2047/4885ALDH1A1 1649/4885CYP2C19 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.